Will the non-reimbursed Gavreto vanish in Korea?

By Jung, Sae-Im | translator Kim, Jung-Ju

23.07.08 05:50:37

가나다라 0

Roche to sell the drug until February next year...will return the rights to Blueprint

The drug failed to receive reimbursement after Roche gave up sales rights...reapplication plan for reimbursement unclear

Retevmo expected to dominate the RET inhibitor market...lowering Gaverto’s expected profit

The possibility that the new RET-targeted anticancer therapy ‘Gavreto (pralsetinib)’ will vanish without ever being released in Korea has been rising. With Roche giving up sales rights for Gavreto, the prospects of its reimbursement listing in Korea had also gone up in smoke. As Blueprint Medicines, the original developer of Gavreto, does not have a branch in Korea, the company would need to find a new partner to market the drug in Korea, which is more easily said than done.

According to the Health Insurance Review and Assessment Service, the Drug Reimbursement Evaluation Committee determined Gavreto inadequate for reimbursement and made a ‘non-reimbursement’ at its 7th 2023 DREC meeting that was h

Jung, Sae-Im (same@dailypharm.com)

If you want to see the full article, please JOIN US (click)